Happenings Archive

What's Happening Now is a quick, thoughtful, real-time briefing regarding material events in the stem cell industry...definitely not the usual stream of insignificant press releases. The most current Happenings are boxed on the left-hand side of most pages on this site. Feel free to use this page to explore the archive of all past Happening items, and subscribe to the RSS feed to stay on top of the events that move the market and the industry.

COMPANY:

BioTime Floats Odd Proposal to Finance Its ESC Development Program
Oct 28, 2013
BioTime (BTX) floated a proposal in a press release suggesting its majority-owned subsidiary, Asterias Biotherapeutics (formed during BioTime's acquisition of Geron's shuttered ESC program), may offer a highly creative financing plan that could amount to a three year interest-free loan of $15 million at investors' expense. The company suggested it plans to file a registration statement with the SEC for the offer in November.
BioTime Completes Acquisition of Geron's ESC Assets
Oct 1, 2013
BioTime (BTX) and Geron jointly announced the completion of BioTime's acquisition of Geron's shuttered embryonic stem cell therapeutic development program in an all-stock deal. A BioTime subsidiary, Asterias Biotherapeutics, will control the assets. Geron shareholders will receive 21% of Asterias' outstanding shares. Fields of use include medical indications in neurology, oncology, orthopedics and cardiovascular.
BioTime shareholders approve new shares for ESC deal
May 24, 2013
BioTime shareholders approved the issuance of 20 million common shares in connection with the company's acquisition of Geron's shuttered embryonic stem cell program, as well as a 70% increase in the number of shares authorized to be issued.
BioTime (BTX) up on addition of new research products
Apr 10, 2013
BioTime (BTX) announced a deal to distribute ProSpec's recombinant proteins, lifting BTX shares over 11%.
BioTime (BTX) Down Sharply On Performance News
Mar 19, 2013
BioTime (BTX) was down sharply this morning on news of its 2012 performance: decreased revenue due in part to lower sales, increased expenses, and a wider net loss than expected. BTX shares were down 10% by mid-morning.
< Previous Page  |  Next Page >